menu
    • menu
    [{"orgOrder":0,"company":"Lynch Regenerative Medicine","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Peptide, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"Platelet-derived growth factor receptor","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Lynch Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Lynch Regenerative Medicine","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Lynch Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Lynch Regenerative Medicine","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lynch Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Lynch Regenerative Medicine \/ Lynch Regenerative Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Lynch Regenerative Medicine

    Menu

    Lynch Regenerative Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lynch Regenerative Medicine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Lynch Regenerative Medicine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Recipient : SMITH & NEPHEW INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration

                            Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.

                            Product Name : Regranex

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 31, 2025

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Recipient : SMITH & NEPHEW INC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lynch Regenerative Medicine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Lynch Regenerative Medicine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human PDGF-BB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Recipient : Vanderbilt University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

                            Details : Recombinant Human PDGF-BB is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wound Healing.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Recombinant Human PDGF-BB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Recipient : Vanderbilt University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lynch Regenerative Medicine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Lynch Regenerative Medicine

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human PDGF-BB

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Alexander Hawkins

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating an RhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing

                            Details : Recombinant Human PDGF-BB is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rectal Fistula.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Recombinant Human PDGF-BB

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Alexander Hawkins

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth